Celldex
Hampton, New Jersey, United States · Biotechnology, Health Care, Medical
Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders.
Key facts
- Headquarters
- Hampton, New Jersey, United States
- Employees
- 190
- Industries
- Biotechnology, Health Care, Medical
- Status
- Public (CLDX)
- Website
- celldex.com
- Company page
Recent activity at Celldex
- : SEC 8-K (8.01): On September 22, 2026, Celldex Therapeutics, Inc. issued a press release announcing the results from its two Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 clinical trials of Barzolvolimab, which targets chronic spontaneous urticaria (CSU). This announcement is significant as it communicates the outcomes of important clinical trials that may impact the company's future product offerings and market strategy. The results could influence investor sentiment and the stock performance of Celldex, as they pertain to the efficacy and potential approval of a new treatment. The press release is attached as Exhibit 99.1.
- : SEC 8-K (1.01): On April 1, 2026, Celldex Therapeutics, Inc. entered into an underwriting agreement with Leerink Partners LLC and TD Securities (USA) LLC for the offering of 10,345,000 shares of its common stock at a public price of $29.00 per share. The anticipated net proceeds from this offering are approximately $282 million after deducting underwriting discounts and expenses. The offering is projected to close around April 6, 2026, contingent on customary closing conditions. This agreement indicates a significant capital raise for the company, which may impact its strategic operations and funding for future initiatives.
- : Celldex Therapeutics Appoints Teri Lawver as Chief Commercial Officer
- : Celldex Therapeutics, Inc.
Celldex funding history
| Date | Round | Amount |
|---|---|---|
| Nov 2016 | Venture | $62.5M |
Leadership
- Chandler Ruehrwein, Senior Director Human Resources
- Bradley Bloom, Vice President Clinical Development
- Neil Wishart, VP of Clinical Strategy
- Vernika Dahiya, Talent Sourcing Recruiter
- Teri Lawver, Chief Commercial Officer
Verified email and direct lines for Celldex’s decision-makers are on Fundz. See plans
Celldex in the news
- Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 - GlobeNewswire (Sep 22, 2026)
- Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting - Yahoo Finance (Jun 14, 2026)
- Celldex Data At 2026 EAACI Puts Mast Cell Pipeline In Focus - simplywall.st (Jun 12, 2026)
- Celldex Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering of Common Stock - Quiver Quantitative (Apr 02, 2026)
- Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis - GlobeNewswire (Jul 21, 2026)
- Celldex to Present at Upcoming Investor Conference - Yahoo Finance (Sep 08, 2026)
- SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX) - Prime Publishers, Inc. (Aug 24, 2026)
- Celldex Reports Second Quarter Financial Results and Provides Corporate Update - The Manila Times (Aug 07, 2026)
Companies similar to Celldex
- Aptose Biosciences · Biotechnology, Health Care, Medical, research, Therapeutics
- Swarm Oncology Ltd · Biotechnology, Health Care, Medical, research, Therapeutics
- Onward Therapeutics SA · Biotechnology, Health Care, Medical, research, Therapeutics
- Genentech · Biotechnology, Health Care, Medical, research, Therapeutics
- Zentalis Pharmaceuticals · Biotechnology, Medical, research, Therapeutics
About Celldex: questions and answers
What does Celldex do?
Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders.
Where is Celldex headquartered?
Celldex is headquartered in Hampton, New Jersey, United States.
How many employees does Celldex have?
Celldex has about 190 employees.
Has Celldex raised funding?
Yes. Fundz has recorded 1 funding event for Celldex. The most recent, $62.5M, was in Nov 2016.
Who leads Celldex?
Bradley Bloom is a Vice President Clinical Development at Celldex.
What is the latest news on Celldex?
On Sep 22, 2026, SEC 8-K (8.01): On September 22, 2026, Celldex Therapeutics, Inc. issued a press release announcing the results from its two Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 clinical trials of Barzolvolimab, which targets chronic spontaneous urticaria (CSU). This announcement is significant as it communicates th
Is Celldex a public company?
Yes. Celldex is publicly traded under the ticker CLDX.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy